Professor, Medicine, UCSF School of Medicine
Internal Medicine
Dr. Emily K. Bergsland, MD
|
|
Give Review
Emily Bergsland works in the field of Internal Medicine. She studied medicine at University of Minnesota Medical School. University of Minnesota Medical School is ranked 40/10 in Research/PrimaryCare. She received 2 awards: "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Emily Bergsland has written publications. She has 56 publications published with PubMed. The lastest paper is: 'Human acellular dermal matrix as a novel model of malignant epithelial cell invasion.' She is registered with Medicare and accepts Medicare payments.
Publications
- Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
- Correcting for respiratory motion in Liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging.
- Bone metastases and skeletal-related events from neuroendocrine Tumors.
- Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with Neuroendocrine tumor.
- Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
- Neuroendocrine Tumors of Unknown Primary: Is the Primary Site Really Not Known?
- B cells regulate macrophage phenotype and response to chemotherapy in squamous Carcinomas.
- (90)Y Glass Microspheres for the Treatment of Unresectable Metastatic Liver Disease from Chemotherapy-Refractory Gastrointestinal Cancers: A Pilot Study.
- A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal Cancer.
- Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
- Temsirolimus combined with sorafenib in hepatocellular Carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
- Lymph Node Sampling Rates and Predictors of Nodal Metastasis in Pancreatic Neuroendocrine Tumor Resections: The UCSF Experience With 149 Patients.
- Systemic therapy for advanced carcinoid tumors: where do we go from here?
- Optimizing the Administration of Fixed-Dose Rate Gemcitabine Plus Capecitabine Using an Alternating-week Schedule: A Dose Finding and Early Efficacy Study in Advanced ...
- Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
- Lack of NKX2.2 expression in bronchopulmonary typical carcinoid Tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
- Identification of unknown primary tumors in patients with neuroendocrine Liver metastases.
- Glycemic control in patients with insulinoma treated with everolimus.
- A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic Cancer: is an anti-VEGF strate...
- Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic Cancer receiving chemotherapy.
- Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic Cancer: results of a phase II study.
- Phase II trial of sunitinib in patients with metastatic colorectal Cancer after failure of standard therapy.
- Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine Cancer?
- A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic Cancer.
- Islet cell Carcinoma: neuroendocrine tumors of the pancreas and periampullary region.
- Phase II study of recombinant human endostatin in patients with advanced neuroendocrine Tumors.
- Pancreatoblastoma in an adult: case report and review of the literature.
- Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenoCarcinoma of the pancreas.
- When does the presence of the target predict response to the targeted agent?
- Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorect...
- Update on clinical trials targeting vascular endothelial growth factor in Cancer.
- Vascular endothelial growth factor as a therapeutic target in Cancer.
- Angiogenesis in colorectal Cancer: therapeutic implications and future directions.
- Immune enhancement of skin carcinogenesis by CD4+ T cells.
- Tumor-associated hypoglycemia from metastatic coloRectal adenocarcinoma: case report and review of the literature.
- Shedding old paradigms: developing viruses to treat Cancer.
- Optimal timing of surgery after chemoradiation for advanced rectal Cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial.
- The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.
- A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic Cancer.
- Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine Tumors.
- Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic Cancer.
- Human acellular dermal matrix as a novel model of Malignant epithelial cell invasion.
- Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.
- Hepatocellular Carcinoma.
- Molecular mechanisms underlying the development of hepatocellular Carcinoma.
- Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
- Couples therapy at end of life.
- Maximizing the potential of bevacizumab in Cancer treatment.
- Anti-angiogenic strategies in gastrointestinal malignancies.
- Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal Cancer.
- Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal Cancer.
- Activity of sunitinib in patients with advanced neuroendocrine Tumors.
- Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory coloRectal carcinoma.
- Arterial thromboembolic events in patients with metastatic Carcinoma treated with chemotherapy and bevacizumab.
- Targeting growth factors and angiogenesis; using small molecules in malignancy.
Schools
University Of Minnesota Medical School
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
UCSF -
University of Minnesota Medical School
Hospital
-
San Francisco General Hospital and Trauma Center -
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1295792729 | |
| NPPES Provider LastName | BERGSLAND | |
| NPPES Provider FirstName | EMILY | |
| NPPES Provider ZIPCode | 941153010 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 77.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1295792729 |
| Last Name Of The Provider | BERGSLAND |
| First Name Of The Provider | EMILY |
| View All |
Similar Doctors
|
|
Dr. Stephanie Wong, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yangchen Dolkar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark D. Smith, MD |
|
|
Dr. Rena K. Fox, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jennifer L. Jarvie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Felix H. Lui, MD |
|
|
Dr. Rupali K. Nabar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Usha K. Sunkara, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ann K. Lanzerotti, MD |
|
|
Dr. Meredith R. Heller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sumit A. Shah, MD
This Doctor is OpenDoctor Recommended.
|